Six-Month Delamanid Regimen Matches Standard Care for Rifampicin-Resistant TB

The BEAT Tuberculosis trial validates a 6-month, all-oral bedaquiline-delamanid-linezolid-based strategy usable in children and pregnant patients where pretomanid is contraindicated.

bedaquilinedelamanidlinezolidlevofloxacinclofaziminerifampicin-resistant tuberculosisMDR-TBdrug-resistant TBnoninferiority trialWHO guidelinesantimicrobial stewardshippediatric TBpregnancy Infectious Disease / Antimicrobials

Background Information

Shorter treatment, same efficacy: a 6-month TB regimen works.

Rifampicin-resistant tuberculosis is challenging to treat, and shorter, effective regimens could improve patient compliance and outcomes. The 6-month regimen was found to be noninferior to the 9-month standard regimen, with similar safety profiles and successful outcomes in 86.1% and 86.0% of participants respectively. This phase 3 trial suggests that a 6-month regimen could be a viable alternative, though long-term studies are needed to confirm sustained efficacy and safety. A 6-month regimen for rifampicin-resistant tuberculosis is as effective as current 9-month treatment.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Conradie F, Badat T, Poswa A, Rajaram S, Kooverjee S, Maartens G, Meintjes G, Hughes J, Schaaf HS, Howell P, Ndjeka N, Phillips PPJ

Citation: Conradie F, Badat T, Poswa A, et al. A Pragmatic Trial of a 6-Month Strategy for Rifampicin-Resistant Tuberculosis. The New England journal of medicine. 2026;394(24):2429-2439. doi:10.1056/NEJMoa2503687

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →